You just read:

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML

News provided by

Daiichi Sankyo Company, Limited

Aug 01, 2018, 08:00 ET